Literature DB >> 9882697

Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes.

D Ma1, P Wu, R W Egan, M M Billah, P Wang.   

Abstract

There are four different genes encoding the cAMP-specific phosphodiesterase (PDE4) isozymes (A, B, C, and D). cAMP has been the only agent known to induce PDE4 gene expression. In the present study, we demonstrate, for the first time, that lipopolysaccharide (LPS) significantly and selectively stimulated PDE4B mRNA production in human monocytes. The LPS stimulation occurred very rapidly (in 30-45 min) and in a dose-dependent manner (0.01-100 ng/ml). We also demonstrate that LPS induction of PDE4B mRNA expression was inhibited strongly by interleukin (IL)-10. The inhibition with IL-10 was dose-dependent (0.1-10 ng/ml). IL-4 also inhibited the LPS induction, but to a lesser extent than IL-10. PDE4B mRNA expression was also stimulated by dibutyryl-cAMP. Interestingly, unlike LPS induction, the dibutyryl-cAMP induction of PDE4B mRNA expression was not inhibited by IL-10. By performing nuclear run-on and mRNA stability assays, we demonstrate further that IL-10 inhibited LPS-stimulated PDE4B mRNA synthesis by abolishing the gene transcription rather than by enhancing mRNA degradation. The present study suggests that PDE4B, as the only LPS-inducible PDE4 subtype, may be an appropriate target for discovering anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882697     DOI: 10.1124/mol.55.1.50

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

2.  The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells.

Authors:  Roxane Hervé; Thomas Schmitz; Danièle Evain-Brion; Dominique Cabrol; Marie-Josèphe Leroy; Céline Méhats
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

3.  Phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes.

Authors:  Elizabeth Borysiewicz; Daniel Fil; Daniel Dlaboga; James M O'Donnell; Gregory W Konat
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

4.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

Authors:  S J MacKenzie; M D Houslay
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

5.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.

Authors:  S-L Catherine Jin; Marco Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

6.  Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

Authors:  A Buenestado; S Grassin-Delyle; F Guitard; E Naline; C Faisy; D Israël-Biet; E Sage; J F Bellamy; H Tenor; P Devillier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury.

Authors:  Christopher M Whitaker; Eric Beaumont; Michael J Wells; David S K Magnuson; Michal Hetman; Stephen M Onifer
Journal:  Neurosci Lett       Date:  2008-04-08       Impact factor: 3.046

8.  Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.

Authors:  Sergey Udalov; Rio Dumitrascu; Soni S Pullamsetti; Hamza M Al-tamari; Norbert Weissmann; Hossein A Ghofrani; Andreas Guenther; Robert Voswinckel; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  BMC Pulm Med       Date:  2010-05-05       Impact factor: 3.317

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.

Authors:  Mousumi Ghosh; Daniela Garcia-Castillo; Vladimir Aguirre; Roozbeh Golshani; Coleen M Atkins; Helen M Bramlett; W Dalton Dietrich; Damien D Pearse
Journal:  Glia       Date:  2012-08-02       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.